未登录

L

Louise Yu

analysis group inc.

H指数:6

被引数:247

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IMPACT OF MEPOLIZUMAB ON INHALED CORTICOSTEROIDS (ICS), SHORT-ACTING BETAAGONISTS (SABA) AND ORAL CORTICOSTEROIDS (OCS) USE IN SEVERE ASTHMA: A RETROSPECTIVE REAL-WORLD STUDY

IF8.6

2024-10-010

PRE

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia

IF7.1

2023-08-097

OAAI

Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study

SCIENTIFIC REPORTS

IF3.9

2023-07-267

OAAI

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors

ADVANCES IN THERAPY

IF4

2021-07-1954

OAAI

Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population

ADVANCES IN THERAPY

IF4

2021-07-1724

OAAI

Real-world genetic testing patterns in metastatic castration-resistant prostate cancer

FUTURE ONCOLOGY

IF2.6

2021-04-2821

OA

Real-world treatment (Tx) patterns of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the US

美国转移性去势抵抗性前列腺癌 (mCRPC) 患者 (pts) 的真实世界治疗 (Tx) 模式

ANNALS OF ONCOLOGY

IF65.4

2020-09-011

OAAI

Real-world patterns of genomic testing in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)

ANNALS OF ONCOLOGY

IF65.4

2020-09-011

OAAI

Real-world treatment (Tx) patterns in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm plus )

ANNALS OF ONCOLOGY

IF65.4

2020-09-010

OAAI